Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Replimune Group Inc

REPL ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$14.97

▼ -1.45%

Market Cap $1.38B · Vol 1.02M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.38B

Small Cap

Div Yield

N/A

EPS Growth

+21.94%

YoY

RSI (14)

70.77

Momentum

Beta

0.97

vs Market

52W High

$15.69

4.59% below

52W Low

$1.50

898.00% above

Volume

1.02M

Avg 1.72M

P/B

3.81

Price-to-book

ROE

-107.88%

Return on equity

Free Float

98.15%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Replimune Group Inc (REPL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does REPL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+24.13%

+51.67%

+203.65%

+87.83%

YTD

+54.01%

+179.81%

-23.15%

-50.43%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-313,940,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-107.88%
ROA · ROIC	-71.17% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.81
P/FCF	N/A
EPS Growth	+21.94%
Outstanding Shares	92.42M

Technical Indicators

50-Day SMA	$10.61
200-Day SMA	$8.14
RSI (14)	70.77
Beta	0.97
52-Week High	$15.69
52-Week Low	$1.50

Volume Today	1.02M
Avg Daily Volume (30D)	1.72M
Relative Volume	0.59x
Volatility (10D)	92.98
Volatility (30D)	264.57
Free Float	98.15%

Analyst Consensus

BUY

Current Price $14.97

Mean Target $13.77

52W Low$1.50 52W High$15.69

Current

Target

$1.50 $15.69

Current Analyst target

-7.99% downside risk · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00L8Z22S0

ISINUS76029N1063

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateAug 7, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.